- Report
- August 2023
- 70 Pages
South Korea
From €4486EUR$4,750USD£3,815GBP
- Report
- October 2022
- 70 Pages
Africa
From €4486EUR$4,750USD£3,815GBP
- Report
- August 2020
- 150 Pages
Global
From €4014EUR$4,250USD£3,414GBP
- Report
- August 2023
- 150 Pages
North America
From €4486EUR$4,750USD£3,815GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €472EUR$500USD£402GBP
Onglyza is a prescription medication used to treat type 2 diabetes. It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the amount of insulin released by the pancreas after meals. Onglyza is used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. It is also used to reduce the risk of major cardiovascular events, such as heart attack and stroke, in adults with type 2 diabetes and established cardiovascular disease.
Endocrine and Metabolic Disorders Drugs are medications used to treat a variety of conditions related to hormones and metabolism. These drugs are used to treat conditions such as diabetes, thyroid disorders, obesity, and other endocrine and metabolic disorders. Onglyza is one of the drugs used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly.
Some companies in the Onglyza market include AstraZeneca, Bristol-Myers Squibb, Merck, and Novo Nordisk. Show Less Read more